phase readout
saveNCT07333118: A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Grit Biotechnology. Phase: EARLY_PHASE1. Conditions: Moderate to Severe Refractory Autoimmune Disease
view source ↗
comments(0)
5-min edit window · permanent after that